Study of efgartigimod for myasthenia gravis crisis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This trial tests a drug called efgartigimod for people with myasthenia gravis who are experiencing a sudden, severe worsening of symptoms (crisis). The drug may help reduce the need for a breathing tube or speed up recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with myasthenia gravis (MG).
- Your MG is causing generalized weakness or trouble breathing (MGFA classes II to V).
- You have a positive antibody test for AChR or MuSK (but up to 3 people may join without these).
- You are having a myasthenic crisis: worsening symptoms that need hospitalization or made it hard to remove a breathing tube after surgery.
- You agree to use effective birth control if you are a man or are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called efgartigimod for people with myasthenia gravis who are in the hospital because their symptoms are getting worse. The goal is to see if it can help them recover faster and avoid needing a breathing tube.
This trial tests if a drug called efgartigimod can help people with generalized myasthenia gravis who have recently had a severe flare-up. Participants will get the drug as maintenance therapy to prevent future crises.
This study tests a new treatment called efgartigimod for people who have been recently diagnosed with generalized myasthenia gravis (gMG). It aims to see if this medicine can help manage symptoms like muscle weakness.
This trial tests multiple treatment combinations for people with myasthenia gravis (MG), a condition that causes muscle weakness. It aims to find safer and more effective options by comparing different therapies.
This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.
This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.
Hear when a new Myasthenia Gravis Crisis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.